Business Express is an online portal that covers the latest developments in the world of business and finance. From startups and entrepreneurship to mergers and acquisitions, Business Express provides reporting on the stories that matter most to business leaders and decision-makers.The website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.
2021 08 25T104942Z 1 LYNXMPEH7O0EP RTROPTP 4 HEALTH CORONAVIRUS J J SAFRICA
2021 08 25T104942Z 1 LYNXMPEH7O0EP RTROPTP 4 HEALTH CORONAVIRUS J J SAFRICA

J&J says booster dose increased antibodies in early-stage studies


By Julie Steenhuysen

CHICAGO (Reuters) – A booster dose of Johnson & Johnson’s COVID-19 vaccine sharply increased levels of antibodies, according to interim data from two early-stage trials, the company said on Wednesday.

A second dose of the J&J single-dose vaccine resulted in binding antibody levels nine times higher than the levels 28 days after people received their first dose, the company said in a press release.

Unlike neutralizing antibodies, which destroy the virus, binding antibodies attach to the virus but do not destroy it or prevent infection. Instead, they alert the immune system of its presence so white blood cells can be sent to destroy it.

Several countries, including the United States, have begun offering booster doses https://www.reuters.com/article/us-health-coronavirus-booster/factbox-countries-weigh-need-for-booster-covid-19-shots-idUKKBN2FP168 to vulnerable individuals, including the immunocompromised, as the Delta variant has spread and some vaccinated people have caught COVID-19.

There has previously been no evidence about the effect of a booster dose of the J&J vaccine. U.S. Centers for Disease Control and Prevention (CDC) advisers in particular have been waiting for word on how to advise immunocompromised individuals who received the J&J vaccine.

According to J&J, the studies showed significant increases in binding antibody responses in participants aged 18-55 and in those 65 years and older who received a lower booster dose.

The study summaries are being submitted to the preprint server MedRxiv in advance of peer review.

The results were released ahead of long-awaited results from J&J’s large, two-dose vaccine trial. A spokesman said those results will be available in the coming weeks.

Don't miss out on any breaking news or insightful opinions!
Subscribe to our free newsletter and stay updated on the go!


By submitting this form, you are consenting to receive marketing emails from: Global Banking & Finance Review. You can revoke your consent to receive emails at any time by using the SafeUnsubscribe® link, found at the bottom of every email.

In July, J&J published interim Phase 1/2a data in the New England Journal of Medicine that showed neutralizing antibodies generated by its vaccine remained stable eight months after immunization with a single dose.

“With these new data, we also see that a booster dose of the Johnson & Johnson COVID-19 vaccine further increases antibody responses among study participants who had previously received our vaccine,” Mathai Mammen, head of research and development at J&J’s Janssen pharma division, said in a statement.

“We look forward to discussing with public health officials a potential strategy for our Johnson & Johnson COVID-19 vaccine, boosting eight months or longer after the primary single-dose vaccination.”

Several scientists have raised concerns that individuals who got the J&J shot would need boosters. One study by a team from New York University found a “significant fraction” of blood samples from recipients who got the J&J shot had low neutralizing antibodies against Delta and several other coronavirus variants.

J&J said the company is working with the CDC, the U.S. Food and Drug Administration, the European Medicines Agency, the World Health Organization and other health authorities about delivering a booster shot with the Johnson & Johnson COVID-19 vaccine.

Because of its one-dose convenience and less onerous storage and shipping requirements, J&J’s shot was once touted as an important tool for vaccinations in hard-to-reach areas. But after safety concerns and manufacturing stumbles, it has the lowest uptake in Europe among all the vaccines approved for use, and has also struggled to gain traction in the United States.

 

(Reporting by Julie Steenhuysen; Editing by Karishma Singh)

Recent Post: